Shadia Jalal is an Oncology physician affiliated with Indiana University Health. OpenAlex indexes 248 publications with 9,722 citations (h-index 40); ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
535 Barnhill Dr
Indianapolis, IN 462025112
Telephone
317-274-5500Provider last certified this registry record 11 Mar 2025.
Clinical trials
- Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
Sponsor: VA Office of Research and Development
- Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer
Sponsor: VA Office of Research and Development
- Rapid Autopsy Protocol for Patients With Small Cell Lung Cancer
Sponsor: Indiana University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
24.7%Atypical Antipsychotic8.6%Olanzapine100%Part D≥11 patientsPhenothiazine6.6%Prochlorperazine Maleate100%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
21.1%Proton pump inhibitor15.2%Omeprazole76%Lansoprazole24%Part D<11 patientsSerotonin-3 Receptor Antagonist5.8%Ondansetron Hcl100%Part D<11 patientsCancer & immunology
16.3%Kinase inhibitor16.3%Tagrisso80%Alecensa20%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2026–2026 per NIH RePORTER. The latest:
- Biomarker Directed trial of Temozolomide and PARP inhibition in relapsed SCLC
Rlr Va Medical Center
FY2026I01CX002801 - Evaluating the impact of intermittent fasting in combination with checkpoint inhibitors in patients with non-small cell lung cancer
Rlr Va Medical Center
FY2026I01CX002843
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network
2025 - Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Douglas Zipes, MD
Indiana University Health
Lawrence Einhorn, MD
Indiana University Health
Lisa Landrum, MD
Indiana University Health
Patrick Loehrer, MD
Indiana University Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”